ReviewESMO open2020
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Cinzia Solinas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
102 papers cite itlatest 60 shown
this paperpooled ittrialcites it